Investigational drug · Phase 3
Survodutide
Also called: BI 456906
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Type 2 Diabetes, Overweight.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
16
Any phase or sponsor naming "Survodutide"
First trial start
2024
Jan 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Survodutide", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Obesity
- Type 2 Diabetes
- Overweight
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Survodutide" as an intervention, largest first.
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07754461 · 600 participants (planned) · Start Aug 24, 2026 · Primary completion Jan 17, 2028
Drug: Placebo; Survodutide · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Gilbert, Arizona; Paradise Valley, Arizona · 121 sites in all
- A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04667377 · 387 participants · Start Mar 8, 2021 · Primary completion Sep 15, 2022
Drug: BI 456906; Placebo · For: Obesity
Sites: Walnut Creek, California; Louisville, Kentucky; Morehead City, North Carolina · 43 sites in all
- A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06214741 · 307 participants · Start Feb 6, 2024 · Primary completion Jul 29, 2025
Drug: survodutide; Placebo matching BI 456906 · For: Obesity; Overweight
Sites: Beijing, China; Changchun, China; Changzhou, China · 28 sites in all
- A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04771273 · 295 participants · Start Apr 27, 2021 · Primary completion Nov 9, 2023
Drug: Survodutide; Placebo · For: Non-alcoholic Steatohepatitis (NASH)
Sites: Huntsville, Alabama; Coronado, California; Huntington Park, California · 154 sites in all
- A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06176365 · 274 participants · Start Jan 16, 2024 · Primary completion Dec 3, 2025
Drug: Survodutide; Placebo matching survodutide · For: Obesity
Sites: Aichi, Nagoya, Japan; Chiba, Chiba, Japan; Gifu, Gifu, Japan · 28 sites in all
- Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseasePivotal-lookingNot yet recruiting
University Medical Center GroningenAcademic, hospital or other
NCT07206290 · 120 participants (planned) · Start Mar 2, 2026 · Primary completion Nov 30, 2027
Drug: Survodutide (BI 456906); Placebo · For: Chronic Kidney Disease
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06200467 · 110 participants · Start Mar 13, 2024 · Primary completion Oct 22, 2025
Drug: Moxifloxacin; Placebo to moxifloxacin · For: Overweight; Obesity
Sites: Mannheim, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT05296733 · 82 participants · Start Apr 27, 2022 · Primary completion Dec 29, 2023
Drug: BI 456906 · For: Healthy; Liver Diseases; Obesity
Sites: Chandler, Arizona; Fort Myers, Florida; Sarasota, Florida · 13 sites in all
- A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06745284 · 64 participants · Start Mar 26, 2025 · Primary completion Nov 1, 2026
Drug: Survodutide; Semaglutide · For: Obesity
Sites: Orlando, Florida; Baton Rouge, Louisiana
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07768813 · 44 participants · Start Sep 2, 2026 · Primary completion Dec 8, 2026
Drug: Survodutide formulation B2 · For: Healthy; Obesity
Sites: Mannheim, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Hamilton A, Thisted L, Ougaard M, et al. · Diabetes Obes Metab 2026
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Amjad MM, Khan MM, Sarwar F, et al. · Diabetes Obes Metab 2026
- Visceral and Ectopic Fat Remodeling with Incretin-Based Therapies in Type 2 Diabetes: Human Imaging Evidence.
Zhang Q, Liu Y, Zhang T · J Multidiscip Healthc 2026
- Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bozkurt B, le Roux CW, Wharton S, et al. · Lancet 2026
- GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
Polepalli KV, Roshni P, Moka S, et al. · Dig Dis 2026
- Renal Effects of Dual GLP-1/Glucagon Receptor Agonism: How Should We SYNCHRONIZE With Emerging Evidence in Type 2 Diabetes and Obesity?
Patoulias D, Karakasis P, Koufakis T · Diabetes Obes Metab 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.